ArticleEuropean archives of psychiatry and clinical neuroscience2026
Superoxide dismutase and glutathione interact to determine cognitive outcome among people with subjective cognitive decline (SCD): a prospective study.
Article in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubjective cognitive decline (SCD) is an early sign of Alzheimer's disease, in which oxidative stress is implicated. Three primary endogenous antioxidants include superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT). This current study aimed to explore the roles of these antioxidants in cognitive outcome of SCD.
methodsSixty-seven adults with SCD were recruited. Cognitive function (assessed by the Alzheimer's disease assessment scale-cognitive subscale [ADAS-cog]), global function (by Alzheimer's Disease Cooperative Study scale for ADL [ADCS-ADL]), and plasma GSH, CAT, and SOD were measured at baseline and two years later.
resultsOver the two-year course, the 67 participants' cognitive performance (mean ADAS-cog score: 5.2 ± 3.4 at baseline vs. 6.1 ± 5.2 at endpoint, P = .062) and global function (ADCS-ADL score: 68.5 ± 10.2 vs. 62.5 ± 13.3, P < .001) showed a deteriorating trend. Their GSH levels fell significantly (3.67 ± 2.70 vs. 2.81 ± 2.51 μm, P = .016), CAT rose (67.7 ± 23.4 vs. 91.9 ± 35.1 nmol/min/mL, P < .001), but SOD remained pretty constant (0.145 ± 0.053 vs. 0.158 ± 0.068 U/mL). Using generalized estimating equations to assess longitudinal changes in ADAS-Cog, we discovered that baseline ADAS-cog score (P < .001), BMI (P = .009), and baseline SOD×GSH interaction (P = .034) were associated with cognitive outcomes.
conclusionsCognitive decline in people with SCD was influenced by baseline cognitive level, BMI, and the interaction between SOD and GSH, suggesting that antioxidant interplay may play a crucial role in regulating oxidative stress and consequently cognitive aging.
Indexed as
Identifiers
42289601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.